NCT02719691View on ClinicalTrials.gov

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 13, 2016

Primary Completion Date

March 18, 2020

Study Completion Date

March 18, 2020

Conditions
Metastatic Breast CancerSolid Tumors
Interventions
DRUG

Alisertib

Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.

DRUG

MLN0128

Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02719691 - Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | Biotech Hunter | Biotech Hunter